The substantial growth in investment value over the past 5 years, coupled with Novo Nordisk's significant market capitalization, suggests a strong and stable performance. This historical performance, especially with an annualized return of 27.13% and an average annual return of 39.15%, indicates a positive outlook for NVO in the short term. Investors may view this track record as a sign of the company's robust financial health and potential for continued growth.